Scholars Central

Conference abstract

Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children

Authors: Tiphaine Adam de Beaumais

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

6-mercaptopurine has until recently had no adequate formulation for pediatric patients with acute lymphoblastic leukemia (ALL). The only oral paraben-free 6-MP liquid formulation named Loulla was developed and evaluated in the target population. Preclinical and clinical evaluation was performed according to a Pediatric Investigation Plan, in order to apply for a Pediatric Use Marketing Authorization. The pre-clinical study assessed the maximum tolerated dosage-volume and evaluated local mucosal toxicity of 28 daily administrations in treated compared to controls gold hamsters. The multi-centre clinical study was single-dose, open-label, crossover trial, conducted in 15 ALL children during maintenance therapy. Bioavailability and palatability of a single 50 mg fixed dose of Loulla compared to 50 mg registered tablets were evaluated in a random order on two consecutive days. Seven blood samples over 9 hours were obtained each day at to determine pharmacokinetic parameters, including Tmax, Cmax, AUC0â??9 and AUC0â??â??. A questionnaire adapted to children testing Loulla palatability and preference for either Loulla or the usual 6-MP tablet was completed. Occurrence of adverse events was determined at study visits by vital sign measurements, patientâ??s spontaneous reporting, investigatorâ??s questioning and clinical examination. The dosage-volume of 75 mg/kg/day was well tolerated in gold hamster. The relative bioavailability of liquid Loulla formulation compared to the reference presentation is 76% for AUCs and 80% for Cmax. The taste of Loulla and the mouth feeling after ingestion compare favorably to the tablet. No adverse event occurred. Pharmacokinetic, palatability and safety data support the use of Loulla in children.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmacovigilance.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacovigilance
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Tiphaine Adam de Beaumais”